| ²é¿´: 745 | »Ø¸´: 6 | |||
[½»Á÷]
ÎÄÏ×·ÖÏí | ÃâÒßµ÷¿ØÁªºÏÉñ¾µ÷¿Ø£¬IFÓÉ11.4Ìá¸ßΪ25.5
|
|||
|
ÃâÒßµ÷¿ØÊÇÖ¸»úÌå¶ÔÍâ½ç´Ì¼¤×ö³öµÄÃâÒß·´Ó¦¹ý³ÌÖУ¬Í¨¹ý¸÷ÖÖµ÷¿Ø»úÖÆÀ´±£³ÖÃâÒ߯½ºâ״̬£¬ÒÔ¼°»Ö¸´Õý³£ÃâÒßÓ¦´ðµÄÄÜÁ¦¡£ ½üÄêÀ´£¬ÃâÒßµ÷¿ØÏà¹ØµÄÑо¿²ã³ö²»Ç2023ÄêÖбêÊý¸ß´ï985¸ö£¬¿É¼û´ó¼Ò¶ÔÓÚÕâÒ»Ñо¿·½ÏòµÄÈÈÖÔ¡£½ñÌìСÖúÊÖ¸ø´ó¼ÒÕûÀíÁ˼¸Æª½üÄê·¢±íµÄ¸ß·ÖÎÄÕ£¬Óë´ó¼Ò¹²Í¬Ñ§Ï°Ò»ÏÂÃâÒßµ÷¿Ø·½ÏòÓÐÄÄЩеÄÑо¿Ë¼Â·¡£ 1¡¢Cell£¨IF=64.5£©£¬C5a-licensed phagocytes drive sterilizing immunity during systemic fungal infection ϵͳÐÔÄîÖé¾ú¸ÐȾÊÇÒ»ÖÖ³£¼ûµÄ¡¢¸ßËÀÍöÂʵÄÒ½ÔºÕæ¾ú¸ÐȾ¡£³öºõÒâÁϵÄÊÇ£¬ËüÒѳÉΪ¿¹²¹ÌåC5°ÐÏòµ¥¿Ë¡¿¹ÌåÖÎÁƵIJ¢·¢Ö¢£¬±íÃ÷C5ÔÚ¿¹Õæ¾úÃâÒßÖоßÓÐÏà¹Ø×÷Óᣱ¾´ÎÑо¿È·¶¨ÁËÔÚÄîÖé¾úѪ֢»¼ÕßÖÐÓÕµ¼µÄ²¹Ìåϵͳ»ùÒòת¼ΪÊ×λµÄÉúÎï;¾¶£¬²¢Ô¤²âÆäÓëÄîÖé¾úѪ֢µÄÏà¹ØÐÔ¡£´Ó»úÖÆÉÏ¿´£¬C5a-C5aR1ͨ¹ý´Ì¼¤ÍÌÊÉϸ°ûЧӦ¹¦ÄÜÒÔ¼°ERKºÍAKTÒÀÀµµÄ¸ÐȾ×éÖ¯´æ»î£¬´Ù½øÐ¡ÊóÈ«ÉíÐÔÄîÖé¾ú²¡Ä£ÐÍÖеÄÕæ¾úÇå³ýºÍËÞÖ÷´æ»î¡£ÇóýC5ar1»ùÒòÖØ¹¹ÁËmTORÏÂÓεľÞÊÉϸ°û´úл£¬´Ù½øÁËËüÃǵĵòÍö£¬²¢Í¨¹ýÉöËðÉËÔö¼ÓÁËËÀÍöÂÊ¡£³ýÁ˸Îϸ°ûÀ´Ô´µÄ C5£¬ÓÉÍÌÊÉϸ°ûÄÚÔ´ÐÔ²úÉúµÄC5ÌṩÁË¿¹Õæ¾ú±£»¤µÄ¹Ø¼üµ×ÎѪÇåµÍC5aŨ¶È»ò¼õÉÙ°×ϸ°û C5±í´ïµÄC5¶à̬ÐÔÓ뻼ÕßÔ¤ºó²»Á¼Ïà¹Ø¡£×ÛÉÏËùÊö£¬¾Ö²¿ÍÌÊÉϸ°û²úÉúµÄC5²úÎïÊÚȨÁËÍÌÊÉϸ°ûµÄ¿¹Î¢ÉúÎ﹦ÄÜ£¬²¢ÔÚÈ«ÉíÕæ¾ú¸ÐȾ¹ý³ÌÖÐÌṩ¹ÌÓб£»¤¡£ 2¡¢Bioactive Materials£¨IF=18.9£©£¬A multifunctional neuromodulation platform utilizing Schwann cell-derived exosomes orchestrates bone microenvironment via immunomodulation, angiogenesis and osteogenesis ×î½üµÄÑо¿Ö¤Ã÷ÁËÔÚ¹ÇÔÙÉúÖÐÖØÏÖ¹Ç΢»·¾³ÖÐµÄ¶à·½ÃæÉúÎïѧÐèÇó¡£Éñ¾»¯¶ÔÓÚʵÏÖ¹Ç×éÖ¯¹¤³Ì£¨BTE£©ÖеĶàϵͳµ÷¿Ø¾ßÓо޴óDZÁ¦¡£È»¶ø£¬ËùÓÐÉæ¼°¹Ø¼ü¹ÇÐÞ¸´²½ÖèµÄÉñ¾²ßÂÔÉÐ䱨µÀ¡£ÔÚ±¾Ñо¿ÖУ¬Éñ¾×éÖ¯¹¤³ÌË®Äý½º·â×°µÄϸ°ûÀ´Ô´ÍâÃÚÌ壨SC Exo£©¡£ÕâÖÖ³ÖÐøÊÍ·ÅµÄ SC Exoϵͳͨ¹ý´Ù½øÌåÄÚµÄÉñ¾»¯¡¢ÃâÒßµ÷½Ú¡¢Ñª¹Ü»¯ºÍ³É¹Ç×÷ÓÃÏÔÖøÔöÇ¿Á˹ÇÔÙÉú¡£´ËÍ⣬ÌåÍâ½á¹û½øÒ»²½È·ÈÏÁ˸ÃϵͳÏÔÖøÓÕµ¼¾ÞÊÉϸ°ûµÄ M2¼«»¯¡¢HUVECsµÄ¹ÜÐγÉÒÔ¼° BMSCsµÄ³É¹Ç·Ö»¯¡£´ËÍ⣬ͨ¹ýÉϵ÷ TGF-¦Â1/SMAD2/3ÐźÅͨ·´Ù½øÁË BMSCsµÄ³É¹Ç¡£×ÛÉÏËùÊö£¬±¾Ñо¿ÖÐ×÷Õ߳ɹ¦¿ª·¢ÁËÒ»ÖÖеÄÎÞϸ°û¡¢Ò×ÓÚÖÆ±¸µÄ SC-ExoÉñ¾¹¤³Ì£¬Í¨¹ýе÷Õû¸ö¹ÇÓúºÏ΢»·¾³À´´Ù½ø¹ÇÔÙÉú£¬Õâ¿ÉÄÜΪ×éÖ¯¹¤³ÌºÍ¹ÇȱËðµÄÁÙ´²ÖÎÁÆÌṩһÖÖвßÂÔ¡£ 3¡¢Immunity£¨IF=32.4£©£¬Restraint of IFN-¦Ã expression through a distal silencer CNS-28 for tissue homeostasis IFN-¦ÃÊDz¸È鶯ÎïÓ¦¶Ô²¡¶¾»òϸ°ûÄÚϸ¾ú¸ÐȾµÄ¹Ø¼üϸ°ûÒò×Ó¡£ËäÈ»Ðí¶àÔöÇ¿×Ó±»ÃèÊöΪ´Ù½øIFN-¦Ã·´Ó¦£¬µ«»¹Ã»Óз¢ÏÖIfng»ùÒòµÄ³ÁĬÒò×Ó¡£Í¨¹ýÔÚIfng»ùÒòλµãÄÚµÄnaive CD4+Tϸ°ûÖмì²éH3K4me1×éµ°°×ÐÞÊΣ¬ÎÒÃǼø¶¨ÁËÒ»¸öÒÖÖÆÒò×Ó£¨CNS-28£©£¬¸ÃÒÖÖÆÒò×ÓÒÖÖÆIfng±í´ï¡£´Ó»úÖÆÉϽ²£¬CNS-28ͨ¹ýÒÔ GATA3ÒÀÀµT-betÒÀÀµµÄ·½Ê½¼õÉÙIfng»ùÒòλµãÄÚµÄÔöÇ¿×Ó-Æô¶¯×ÓÏ໥×÷ÓÃÀ´Î¬³ÖIfng³ÁĬ¡£ÔÚ¹¦ÄÜÉÏ£¬CNS-28ÔÚÏÈÌìÃâÒß·´Ó¦ºÍÊÊÓ¦ÐÔÃâÒß·´Ó¦ÆÚ¼äÒÖÖÆ NK ϸ°û¡¢CD4+ϸ°ûºÍ CD8+Tϸ°ûÖÐµÄ Ifngת¼¡£´ËÍ⣬ÓÉÓÚ IFN-¦Ã ±í´ïÉý¸ß£¬CNS-28 ȱ·¦µ¼ÖÂ2ÐÍ·´Ó¦±»ÒÖÖÆ£¬´Ó¶ø¸Ä±äÁËTh1ºÍTh2µÄģʽ¡£Òò´Ë£¬CNS-28»îÐÔͨ¹ýÓëIfng»ùÒòλµãÄ򵀮äËûµ÷¿ØË³Ê½Ôª¼þºÏ×÷£¬×î´óÏ޶ȵؼõÉÙ×ÔÉíÃâÒߣ¬´Ó¶øÈ·±£ÃâÒßϸ°û¾²Ö¹¡£ 4¡¢Nature Immunology£¨IF=30.5£©£¬Transcription factor EGR2 controls homing and pathogenicity of TH17 cells in the central nervous system TH17¼È±£»¤ÆÁÕÏ×éÖ¯ÓÖ´¥·¢×ÔÉíÃâÒß¡£ÕâЩ¶ÔÁ¢½ø³Ì±³ºóµÄ»úÖÆÉв»Çå³þ¡£±¾Ñо¿Öз¢ÏÖת¼Òò×ÓEGR2¿ØÖÆÖÐÊàÉñ¾ÏµÍ³£¨CNS£©ÖÐÖ²¡ÐÔTH17ϸ°ûµÄת¼³ÌÐò£¬µ«²»¿ØÖÆÆÁÕÏλµãµÄ±£»¤ÐÔTH17µÄת¼³ÌÐò¡£¶à·¢ÐÔÓ²»¯Ö¢»¼ÕߺÍ×ÔÉíÃâÒßÐÔÉñ¾Ñ×֢СÊóµÄËèÇÊ·´Ó¦ÐÔCD4+Tϸ°ûÖÐ EGR2ÏÔÖøÉý¸ß¡£EGR2ת¼³ÌÐò¾²Ä¬±àÖ¯ÔÚTH17ϸ°ûת¼µ÷¿ØÍøÂçÖУ¬²¢ÓëºËÐÄTH17ϸ°ûÌØÒìÐÔת¼Òò×ÓÖ®¼ä¾ßÓеĸ߶Ȼ¥ÁªÐÔ¡£´Ó»úÖÆÉϽ²£¬EGR2ͨ¹ýÉϵ÷Ó벡ÀýÏà¹Ø»ùÒòºÍËèÑùµ¥ºËϸ°ûÇ÷»¯Òò×Ó£¬ÔöÇ¿ TH17ϸ°û·Ö»¯ºÍËèÑùϸ°ûÏòCNSµÄ=¡£Egr2µÄTϸ°ûÌØÒìÐÔÇóýÔÚ²»Ëðº¦ËÞÖ÷¿ØÖƸÐȾÄÜÁ¦µÄÇé¿öϼõÇáÁËÉñ¾Ñ×Ö¢¡£×ÛÉÏËùÊö£¬EGR2ÔÚCNSµÄ²¡ÔÐÔTH17ϸ°ûÖе÷¿Ø×éÖ¯ÌØÒìºÍ¼²²¡ÌØÒ칦ÄÜ¡£ |
» ²ÂÄãϲ»¶
FDAºË²é Ñз¢»ú¹¹
ÒѾÓÐ1È˻ظ´
¹ú¼Ò¸ß²ã´ÎÈ˲ÅÀîÐËÊç½ÌÊÚ¿ÎÌâ×éÕÐÊÕ²©Ê¿Ñо¿Éú
ÒѾÓÐ39È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ97È˻ظ´
¼ºÍª¿É¿É¼î¹ýÑõ»¯ÔÓÖÊÏÞ¶È
ÒѾÓÐ2È˻ظ´
ÇóÖúIsoeugenolÖÊÁ¿±ê×¼
ÒѾÓÐ0È˻ظ´
Gliclazide
ÒѾÓÐ0È˻ظ´
ÈûÌæÅÉ/àçÌæßߣ¨Thiotepa£© ÖÊÁ¿¿ØÖÆ
ÒѾÓÐ15È˻ظ´
ÓÐûÓдóÀпÉÒÔ°ïæ²éÏÂTrijardy XRºÍQternmet XRÀúÄêÏúÊÛÊý¾Ýѽ
ÒѾÓÐ0È˻ظ´
õ£°·Ë®½âÇóÖú
ÒѾÓÐ11È˻ظ´
» ÇÀ½ð±ÒÀ²£¡»ØÌû¾Í¿ÉÒԵõ½:
Öйú¿ÆÑ§Ôº´óѧÄÉÃ׿ÆÑ§Ó빤³ÌÑ§ÔºÌÆÖÇÓ£¨Ôº³¤£©-ÕÅÒøÍŶÓÕÐÆ¸ÆôÊÂ
+1/176
³É¶¼Àí¹¤´óѧȫ¹úÖØµãʵÑéÊÒ¹«¿ª³ÏƸÂÌÉ«ÓлúºÏ³É·½ÏòÁªÅàÉú¼°¿ÆÑÐÖúÀí
+1/79
ÉϺ£´óѧ¹ÜÀíѧԺÑô·¢¾ü½ÌÊÚ¿ÎÌâ×éȫְ²©Ê¿/²©Ê¿ºóÕÐÆ¸ÆôÊÂ
+1/78
¼±ÕÐ̼²ÄÁÏÏà¹ØÌØÈÎÑо¿ÈËÔ±/²©Ê¿ºó/¿ÆÑÐÖúÀí/26¼¶²©Ê¿ºÍ˶ʿ
+1/49
2026²©Ê¿ÉêÇ롪¡ªÓлú»¯Ñ§\¼ÆË㻯ѧ\Ò©Îﻯѧ·½Ïò
+1/44
Î÷±±¹¤Òµ´óѧÎÞÈË·ÉÐÐÆ÷¼¼ÊõÈ«¹úÖØµãʵÑéÊÒÄâÕÐÊÕµç»ú/×Ô¶¯»¯·½Ïò²©Ê¿1~2Ãû
+1/34
2026Äê»ÆºÓ¿Æ¼¼Ñ§ÔºÄÉÃ×¹¦ÄܲÄÁÏÑо¿ËùÕÐÆ¸
+2/32
ºâˮѧԺÕÐÊÕʳƷÓëÓªÑø·½ÏòÁªºÏÅàÑøÑо¿Éú
+1/30
Î÷ÄϽ»Í¨´óÑ§Ç°ÑØÔºÌ¼ÖкÍÓëÎïÖÊÑ»·ÀûÓÿÎÌâ×éÕÐÊÕ²©Ê¿Éú
+1/29
Õ÷Å®ÓÑ @³¤°²
+1/29
ôßÄÏ´óѧÀí¹¤Ñ§Ôº ¹â×Ó¼¼ÊõÑо¿Ôº¶ÎÐûÃ÷ÍŶÓÉêÇëÖÆ¶Á²©ÕÐÉú
+1/28
¹ú¼Ò¼¶È˲ſÎÌâ×éÕÐÊÕÉúÎïѧÏà¹Ø×¨Òµ2026ÄêÈëѧ²©Ê¿Éú
+1/19
²©Ê¿ÕÐÉú£üÄϾ©¹¤Òµ´óѧÕÐÊÕ2026ÄêÈ«ÈÕÖÆÑ§Êõ²©Ê¿£¨¹©ÈÈ¡¢¹©È¼ÆøÍ¨·çÓë¿Õµ÷£©
+1/14
ÖØÇì´óÑ§Ç°ÑØÔº£¬»ÆÐ¡Ñó½ÌÊÚ¿ÎÌâ×飬ÕÐÊÕ2026Äê·Ç¾ùÏà´ß»¯·½ÏòѧÊõ²©Ê¿2Ãû
+1/9
·Ï¾ÉËÜÁÏÈȽâÓͲɹº
+1/7
´úË㣡²ÄÁÏѧÀíÂÛ¼ÆËã
+1/7
ÉîÈÝSCIÖÇÄÜÌåËÄ´óÄ£¿é£ºMethod, Introduction, Discussion, Abstract
+1/3
ÉϺ£½»Í¨´óѧÆÖ½¹ú¼ÊѧԺ 2026Äê¶È¡°¿ÆÑмûϰÏîÄ¿¡±±¨Ãû֪ͨ
+1/3
Çó¡¶»¯¹¤ÔÀí¡·µÚËÄ°æ ²ñ³Ï¾´¡¢¼ÖÉÜÒå µç×ӽ̲ļ°¿Î¼þ
+1/3
ºþÄÏ´óѧ»úеÓëÔËÔØ¹¤³ÌѧԺÕÔÑÒ¸±½ÌÊÚ¿ÎÌâ×éÕÐÉú2026¼¶ÆÕͨ²©Ê¿Éú1Ãû
+1/2
6Â¥2024-08-06 16:40:20
¼òµ¥»Ø¸´
tzynew2Â¥
2024-08-06 08:47
»Ø¸´
ÉúÎïҽҩʵÑéÍâ°(½ð±Ò+1): лл²ÎÓë
i ·¢×ÔСľ³æAndroid¿Í»§¶Ë
zusn3Â¥
2024-08-06 10:50
»Ø¸´
nono20094Â¥
2024-08-06 11:57
»Ø¸´
ÉúÎïҽҩʵÑéÍâ°(½ð±Ò+1): лл²ÎÓë
¡¤
tfang5Â¥
2024-08-06 16:00
»Ø¸´
ÉúÎïҽҩʵÑéÍâ°(½ð±Ò+1): лл²ÎÓë
¸ý³½ÐÁ³ó7Â¥
2024-08-06 17:13
»Ø¸´







»Ø¸´´ËÂ¥